At Clark Health, we are always looking for the next “big thing” in healthcare. With several neuroscience graduates in our team and our broad experience working on neurology products, it’s an area we like to keep an eye on. Like many other disease areas, breakthroughs in the world of neuroscience are incredibly rare, so when a Huntington’s disease treatment made new ground earlier this year1, it created waves of excitement and we’ve been watching this space ever since. Read more
Recently, there have been a number of reports and studies exploring the potential therapeutic applications of currently illicit drugs. Cannabis is breaking down barriers in the treatment of certain types of epilepsy in the UK and a marketing application for an intranasal esketamine spray has been submitted to the EMA for treatment-resistant major depressive disorder.
Currently available antidepressants, such as SSRIs, are used collectively to treat major depressive disorder, anxiety and other mood disorders. They have been shown to lack substantial efficacy in all patient populations and are renowned for having a delayed onset of action (Penn and Tracy, 2012). Working in the area of mental health at CHC, coupled with an interest to find out more, we ventured further into a current avenue of research that looked more and more curious…
Patient-Pharma interactions are vital for drug development, but are often seen in a negative light. There will always be sceptics; those who think pharma companies have cynical intentions when approaching patients, and conversely, those who feel some patients advocate for the wrong motives. However, in recent years patient advocacy has become a pivotal aspect of the drug development process, where pharma companies have increasingly sought the unique insight that patients can offer.
So can there be a healthy and mutually beneficial relationship between patients and pharmaceutical companies? Read more